| Autor: |
Lutchminarain K; National Health Laboratory Service, Durban, South Africa, University of KwaZulu Natal, Durban, South Africa., Kajee A; National Health Laboratory Service, Durban, South Africa, University of KwaZulu Natal, Durban, South Africa., Gandhi NR; Emory University Rollins School of Public Health, Atlanta, GA, Emory University School of Medicine, Atlanta, GA, USA., Han KSS; National Health Laboratory Service, Durban, South Africa, University of KwaZulu Natal, Durban, South Africa., Mvelase N; National Health Laboratory Service, Durban, South Africa, University of KwaZulu Natal, Durban, South Africa. |
| Abstrakt: |
BACKGROUND: The GenoType MTBDR sl v2 is a molecular test designed for the rapid detection of resistance to second-line anti-TB drugs in Mycobacterium tuberculosis complex (MTBC). OBJECTIVE: To assess the use of MTBDR sl in a programmatic setting and to describe the resistance patterns in a high HIV-TB-endemic area in South Africa. METHODS: We performed a retrospective data analysis of all MTBDR sl results in patients with newly diagnosed rifampicin-resistant TB (RR-TB). We compared its performance on direct testing of smear-positive and smear-negative specimens. Results were examined to observe the detected resistance-conferring mutations. RESULTS: Of 1873 RR-TB/multidrug-resistant TB (MDR-TB), 37.4% were smear-negative and 62.5% were smear-positive. Among smear-negative specimens, the MTBDR sl showed an inconclusive rate of 61.2%, while the inconclusive rate from smear-positive specimens was 6.6%. The most common mutation observed in case of fluoroquinolone resistance occurred at the gyr A gene, codon 90 (A90V) (61/158, 38.6%), and the most common mutation in injectable aminoglycoside resistance occurred in the rrs region, A1401G (71/108, 65.7%). CONCLUSION: In HIV-TB-prevalent settings, routine use of the MTBDR sl is more effective when performed directly on smear-positive specimens. In view of currently used injectable-free regimens, this test requires revision. |
